Mania - Articles - Page 2 | CARLAT PUBLISHING

10 Psychopharm Commandments #1

September 5, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Antidepressants in mania and stimulants in psychotic disorders get called out in our first psychopharm commandment.

Management of Psychogenic Polydipsia

July 11, 2022

Victoria Hendrick, MD and Zachary Davis

Psychogenic polydipsia (PP), also known as primary polydipsia and potomania, was first described in the 1930s. It is surprisingly common with a prevalence rate between 3 to 25% in institutionalized patients. In this podcast, we will discuss how to accurately diagnose and manage psychogenic polydipsia in patients.

EXPERT Q&A

Personality Changes Later in Life: Diagnostic and Treatment Considerations

July 1, 2022

Rajesh R. Tampi, MD, MS, DFAPA.

Rajesh R. Tampi, MD

Professor and chairman, Department of Psychiatry, Bhatia Family Endowed Chair in Psychiatry, Creighton University School of Medicine. Catholic Health Initiatives (CHI) Behavioral Health Services, Omaha, NE.

Dr. Tampi, expert for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Dr. Rajesh R. Tampi describes the course of personality disorders as patients age and provides documentation tips for clinicians who suspect personality disorders.

Thyroid Augmentation in Bipolar Disorder

April 5, 2022

Tammas Kelly, MD.

Tammas Kelly, MD. Clinical Assistant Professor of Psychiatry at the Jacobs School of Medicine and Clinical Associate Professor of Psychiatry at the George Washington University School of Medicine. Author of The Art and Science of Thyroid Supplementation for the Treatment of Bipolar Depression. Dr. Kelly has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A primer on the role of thyroid augmentation in bipolar depression, including dosing tips, side effects, interactions, and when and if to perform labs. With Tammas Kelly, MD.

How to Diagnose Bipolar Disorder

November 5, 2021

Gordon Parker, MD, PhD, DSc.

Gordon Parker, MD, PhD, DSc. Scientia Professor of psychiatry at the University of New South Wales. In 2002 he founded the Black Dog Institute, a clinical research center for mood disorders. Dr. Parker’s research has focused on the phenomenology and diagnosis of depression and bipolar disorder. Dr. Parker has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Gordon Parker takes on the DSM and offers up a practical approach to diagnosing bipolar disorder. Included is a new self-rated scale that Dr. Parker developed to separate normal good moods from hypomania.

Brexpiprazole Ineffective in Mania

September 28, 2021

Richard Moldawsky, MD.

Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Choosing an antipsychotic in bipolar disorder just got more complicated. This series of industry-sponsored trials reveals that their anti-manic activity may not be a class effect.

Mood Stabilizers: What You Don’t Know Can Hurt Them

October 6, 2020

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are many mood stabilizers to choose from, but which ones are the best tolerated? This meta-analysis looks at how they stack up in terms of weight gain, sedation, and overall discontinuation.

Who Should Get Lithium?

September 3, 2020

Janusz Rybakowski, MD, PhD

Janusz Rybakowski, MD, PhD

Janusz Rybakowski is a pioneer in lithium research who has authored over 500 articles on clinical psychiatry. He is a professor of psychiatry at Poznan University in Poland, former chairman of psychiatry at the Medical Academy Bydgoszcz, and author of an upcoming textbook on lithium. Dr. Rybakowski has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Some patients respond so well to lithium that they rarely need other interventions. Janusz Rybakowski sums up what we know about the optimal lithium responder, how to use this underutilized medication, and what lithium’s antiviral properties mean in the era of COVID-19.

RESEARCH UPDATE

Two Augmentation Strategies Compared in Bipolar I

September 3, 2020

Richard Moldawsky, MD

Richard J. Moldawsky, MD. Dr. Moldawsky has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Carbamazepine or valproic acid? Both have been used to augment lithium for decades, but which one works best? A new trial tests them head-to-head.

Pros and Cons of Using Oxcarbazepine Over Carbamazepine

August 28, 2020

Does the limited research support that oxcarbazepine is a safer and more effective treatment for bipolar disorder than its FDA-approved cousin, carbamazepine? Here is an overview of the pros and cons from a previous article in The Carlat Psychiatry Report.Pros:Similar effectiveness as other mood stabilizers. In mania and mixed states,...